ADC Therapeutics SA

What they do

ADC Therapeutics develops and commercializes antibody drug conjugates, with in-house chemistry, manufacturing and controls capabilities managed through a network of third-party contract manufacturing organizations. Its portfolio centers on ZYNLONTA, approved as a monotherapy in the 3L+ DLBCL setting under accelerated approval in the U.S. and conditional approval from the European Commission, China NMPA and Health Canada. The company is running combination trials, LOTIS-5 with rituximab and LOTIS-7 with glofitamab, to move ZYNLONTA into earlier lines of DLBCL and into indolent lymphomas such as marginal zone lymphoma and follicular lymphoma.

Revenue drivers

• ZYNLONTA monotherapy in 3L+ DLBCL — Sales of ZYNLONTA as a single agent in relapsed or refractory DLBCL after two or more lines of systemic therapy; this is the only approved product and effectively the entirety of reported revenue.
• Combination development: LOTIS-5 (rituximab) — A confirmatory Phase 3 trial evaluating ZYNLONTA plus rituximab versus R-GemOx in r/r DLBCL after one or more lines; not yet an approved regimen and represents potential future revenue rather than current sales.
• Combination development: LOTIS-7 (glofitamab) — A Phase 1b trial of ZYNLONTA plus glofitamab in r/r DLBCL that completed enrollment of 100 patients at a 150 g/kg ZYNLONTA starting dose; if successful, management says it could support a second-line-plus position.
• International commercialization via partnerships — ZYNLONTA approvals in Europe, China, Canada and other markets are pursued through strategic partnerships; the 10-K describes continued global expansion as a revenue strategy but the filings do not break out international product revenue.

Recent performance

Second quarter 2026 net product revenue was $18.6 million, and second quarter 2025 revenue was $15.8 million with fourth quarter 2025 revenue of $30.1 million. Full-year revenue rose from $69.1 million in 2023 and $70.8 million in 2024 to $81.4 million in 2025. The company remained deeply unprofitable, with a 2025 net loss of $142.6 million and operating cash flow of negative $141.2 million for the year. As of June 30, 2026, cash and cash equivalents were $219.1 million against total liabilities of $507.6 million and shareholder equity of negative $228.2 million. Management said 3L+ DLBCL monotherapy sales were broadly in line with recent quarters and that it anticipates growth starting in 2027.

Strategy

The stated priority is maximizing ZYNLONTA, first by driving 3L+ DLBCL utilization and second by expanding into earlier lines through LOTIS-5 and LOTIS-7 and into indolent lymphomas through investigator-initiated trials. Following a pre-sBLA meeting with the FDA, the company is assessing the best regulatory path to full approval and earlier-line advancement after the agency raised benefit-risk concerns about the LOTIS-5 data. The company announced a strategic reorganization on June 24, 2026, including a global workforce reduction of approximately 17%, expected to be substantially complete by September 30, 2026, driven by the expected completion of LOTIS-5 and LOTIS-7 and by operational efficiencies. It also plans to submit LOTIS-7 and MZL data to the FDA for Breakthrough Designation and to submit data for publication and potential compendia inclusion. Spending on ADCT-241, an exatecan-based PSMA-targeting ADC, has reached completed IND-enabling activities, and the company continues to explore partnership opportunities.

Risks

• Reliance on a single product — Revenue is effectively limited to ZYNLONTA, so any commercial, regulatory or competitive setback to that one product directly affects all results.
• Accelerated approval and regulatory uncertainty — ZYNLONTA's 3L+ DLBCL approval is accelerated, and after the pre-sBLA meeting the FDA noted substantial concerns regarding the benefit-risk or verification of clinical benefit in LOTIS-5 given the Grade 5 event imbalance, leaving the path to full approval unresolved.
• Negative equity and continuing losses — At June 30, 2026, total liabilities of $507.6 million exceeded total assets of $279.4 million, producing shareholder equity of negative $228.2 million, and the company has recorded annual net losses every year shown, including $142.6 million in 2025.
• Indebtedness and royalty obligations — The 10-K cites restrictive covenants under the Loan Agreement with affiliates of Oaktree Capital Management and Owl Rock Capital Advisors, and states that the HCR Agreement reduces the cash the company can generate from ZYNLONTA sales and licensing and could make it a less attractive acquisition target.

Outlook

Management says it anticipates revenue growth starting in 2027, supported by continued 3L+ DLBCL commercialization and potential compendia inclusion, and that LOTIS-7 and MZL data will be submitted to the FDA for Breakthrough Designation. The company plans to provide an update on regulatory strategy and timing in the near future after the FDA's feedback on the LOTIS-5 pre-sBLA meeting. It also says it is assessing a Phase 3 trial for ZYNLONTA plus glofitamab, which it describes as the most compelling combination data generated to date in 2L+ DLBCL.